The International Treatment Preparedness Coalition (ITPC) welcomes encouraging new evidence from an international study, Strategic Timing of AntiRetroviral Treatment, or START for short. “It is exciting to see that we now have data that provides concrete evidence of the clinical benefits of starting people early on HIV treatment,” explains Christine Stegling, Executive Director of ITPC. […]
On April 15, 2015, the All-Ukrainian Network of People Living with HIV and AIDS convened a roundtable meeting titled Patent Barriers on Medicines: Potential Opportunities to Overcome the Barriers. The meeting brought together representatives of Indian and Ukrainian generic manufacturers in order to identify opportunities to overcome patent barriers through the use of compulsory licensing, […]
New York, May 5, 2015 — On the eve of pharmaceutical company Gilead Sciences’ annual shareholder meeting, thousands of people who have hepatitis C virus (HCV) and HCV/HIV coinfection, with their allies and physicians, have demanded that Gilead change its policies that deny access to treatment for millions of people in developing countries. “Gilead must […]
The International Treatment Preparedness Coalition (ITPC) supports the patent pre-grant opposition that was filed on 13 April 2015 by the Fundación Grupo Efecto Positivo (FGEP) and the Argentinian Network of Positive People (Redar Positive). The patent was filed at Argentina’s patent office and challenges the validity of a patent application submitted by Gilead Sciences on […]
On Human Rights Day, the International Treatment Preparedness Coalition (ITPC) is proud to announce that our Advocacy for Community Treatment (ACT) Toolkit is now available in English, French, Spanish and Russian. The ACT Toolkit facilitates community activists to become effective advocates for HIV treatment access. It includes a special focus on supporting key populations and ensuring everyone’s right to health is respected.
FOR IMMEDIATE RELEASE SEPTEMBER 19, 2014 A Step Back for Millions of People with Hepatitis C: Why Gilead’s Recent Deal with Generic Producers for its Hepatitis C Drugs (Sofosbuvir and Ledipasvir) is a Sham Hepatitis C Virus (HCV) Treatment: Gilead Sciences Voluntary License Under the pretext of increasing access to its hepatitis C treatment, the […]
Following an intensive period of internal reflection and external review, ITPC is proud to present our new strategic plan. The new plan will guide our work over the next three years and outlines….
On 9-13 March 2015, ITPC, in collaboration with the Aids and Rights Alliance for Southern Africa (ARASA), facilitated an HIV and TB financing activist workshop aimed at strengthening key population advocacy for the best use of Global Fund resources and sustainable funding for HIV & TB in Botswana, Malawi and Tanzania. The meeting brought together […]
And this is exactly what ITPC has been advocating for at global level for so many years: for treatment programmes to work in the long run, you need to support community-initiated and -run treatment education projects…
The project, which is supported by UNITAID, will take place over the next three years and aims to remove patent barriers to generic competition in Argentina, Brazil, Ukraine and Thailand by reforming patent laws, challenging undeserved patents and advocating for the selective use of compulsory licenses. The three-day meeting was held at the Merlin Hotel […]
Sign ITPC’s petition to Gilead A recent decision by India’s Patent Office rejecting one of Gilead’s key patents for sofosbuvir is an important step for treatment activists. But Gilead is using every trick in the book to get the decision reversed, including lobbying the Indian Government. Sign our petition today to expand Hep C treatment!
News summary On November 24-28, 2014, the International Treatment Preparedness Coalition (ITPC) and the AIDS and Rights Alliance for Southern Africa (ARASA) held a joint workshop training, titled Community Involvement in Access to Affordable HIV Treatment: Focus on the Influence of Intellectual Property & Free Trade Agreements, at the Aviator Hotel in Johannesburg, South Africa. […]